Advertisement
Clinical Therapeutics
Advanced searchSave search
Original research| Volume 25, ISSUE 11, P2797-2808, November 2003

Efficacy and tolerability of oral stevioside in patients with mild essential hypertension: A two-year, randomized, placebo-controlled study

DOI:https://doi.org/10.1016/S0149-2918(03)80334-X
Efficacy and tolerability of oral stevioside in patients with mild essential hypertension: A two-year, randomized, placebo-controlled study
Previous ArticleA multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia
Next ArticleChange in opioid use after the initiation of gabapentin therapy in patients with postherpetic neuralgia
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Background: Stevioside, a natural glycoside isolated from the plant Stevia rebaudiana Bertoni, has been used as a commercial sweetening agent in Japan and Brazil for >20 years. Previous animal and human studies have indicated that stevioside has an antihypertensive effect.
      Objectives: This study was undertaken to investigate the long-term (2-year) efficacy and tolerability of stevioside in patients with mild essential hypertension. Secondary objectives were to determine the effects of stevioside on left ventricular mass index (LVMI) and quality of life (QOL).
      Methods: This was a multicenter, randomized, double-blind, placebo-controlled trial in Chinese men and women aged between 20 and 75 years with mild essential hypertension (systolic blood pressure [SBP] 140–159 mm Hg and diastolic blood pressure [DBP] 90–99 mm Hg). Patients took capsules containing 500 mg stevioside powder or placebo 3 times daily for 2 years. Blood pressure was measured at monthly clinic visits; patients were also encouraged to monitor blood pressure at home using an automated device. LVMI was determined by 2-dimensional echocardiography at baseline and after 1 and 2 years of treatment. QOL was assessed using the Medical Outcomes Study 36-Item Short-Form Health Survey. Electrocardiographic, laboratory, and QOL parameters were assessed at the beginning of treatment, and at 6 months, 1 year, and 2 years.
      Results: One hundred seventy-four patients (87 men, 87 women) were enrolled in the study, and 168 completed it: 82 (42 men, 40 women; mean [SD] age, 52 [7] years) in the stevioside group and 86 (44 women, 42 men; mean age, 53 [7] years) in the placebo group. After 2 years, the stevioside group had significant decreases in mean (SD) SBP and DBP compared with baseline (SBP, from 150 [7.3] to 140 [6.8] mm Hg; DBP, from 95 [4.2] to 89 [3.2] mm Hg; P < 0.05) and compared with placebo (P < 0.05). Based on patients' records of self-monitored blood pressure, these effects were noted beginning ∼1 week after the start of treatment and persisted throughout the study. There were no significant changes in body mass index or blood biochemistry, and the results of laboratory tests were similar in the 2 groups throughout the study. No significant difference in the incidence of adverse effects was noted between groups, and QOL scores were significantly improved overall with stevioside compared with placebo (P < 0.001). Neither group had a significant change in mean LVMI. However, after 2 years, 6 of 52 patients (11.5%) in the stevioside group had left ventricular hypertrophy (LVH), compared with 17 of 50 patients (34.0%) in the placebo group (P < 0.001). Of those who did not have LVH at baseline, 3 of 46 patients (6.5%) in the stevioside group had developed LVH after 2 years, compared with 9 of 37 patients (24.3%) in the placebo group (P < 0.001).
      Conclusions: In this 2-year study in Chinese patients with mild hypertension, oral stevioside significantly decreased SBP and DBP compared with placebo. QOL was improved, and no significant adverse effects were noted.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Kannel W.B.
        • Belanger A.J.
        Epidemiology of heart failure.
        Am Heart J. 1991; 121: 951-957
        • Klag M.J.
        • Whelton P.K.
        • Randall B.L.
        • et al.
        Blood pressure and end-stage renal disease in men.
        N Engl J Med. 1996; 334: 13-18
        • MacMahon S.
        • Peto R.
        • Cutler J.
        • et al.
        Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias.
        Lancet. 1990; 335: 765-774
        • Stamler J.
        • Stamler R.
        • Neaton J.D.
        Blood pressure, systolic and diastolic, and cardiovascular risks. US population data.
        Arch Intern Med. 1993; 153: 598-615
      5. The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure.
        Arch Intern Med. 1988; 148: 1023-1038
        • Collins R.
        • Peto R.
        • MacMahon S.
        • et al.
        Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context.
        Lancet. 1990; 335: 827-838
      7. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
        Arch Intern Med. 1997; 157: 2413-2446
        • Bulpitt C.J.
        Quality of life in antihypertensive patients.
        in: Amery A. Hypertensive Cardiovascular Disease: Pathophysiology and Treatment. Kluwer Publishers, Boston1982: 929-948
        • Najman J.M.
        • Levine S.
        Evaluating the impact of medical care and technologies on the quality of life: A review and critique.
        Soc Sci Med. 1981; 15: 107-115
        • Melis M.S.
        • Sainati A.R.
        Participation of prostaglandins in the effect of stevioside on rat renal function and arterial pressure.
        Bras J Med Biol Res. 1991; 24: 1269-1276
        • Melis M.S.
        • Macial R.E.
        • Sainati A.R.
        Effects of indomethacin on the action of stevioside on mean arterial pressure and on renal function in rats.
        IRCS Med Sci. 1985; 13: 1230-1231
        • Boeckh E.M.A.
        • Humboldt G.
        Cardio-circulatory effects of total water extract in normal individuals and of stevioside in rats [in Portuguese].
        Cienc Cultura. 1981; 32: 208-210
        • Chan P.
        • Xu D.Y.
        • Liu J.C.
        • et al.
        The effect of stevioside on blood pressure and plasma catecholamines in spontaneously hypertensive rats.
        Life Sci. 1998; 63: 1679-1684
        • Kao P.F.
        • Hsu Y.H.
        • Lee C.N.
        • et al.
        Hypotensive effect of intravenous stevioside in conscious and anesthetized animals.
        N Taipei J Med. 2001; 3: 176-181
        • Hsu Y.H.
        • Liu J.C.
        • Kao P.F.
        • et al.
        Antihypertensive effect of stevioside in different strains of hypertensive rats.
        Zhonghua Yi Xue Za Zhi (Taipei). 2002; 65: 1-6
        • Chan P.
        • Tomlinson B.
        • Chen Y.J.
        • et al.
        A double-blind placebo-controlled study of the effectiveness and tolerability of oral stevioside in human hypertension.
        Br J Clin Pharmacol. 2000; 50: 215-220
        • Guidelines Subcommittee
        1999 World Health Organization—International Society for Hypertension Guidelines for the Management of Hypertension.
        J Hypertens. 1999; 17: 151-183
        • Frohlich E.D.
        • Grim C.
        • Labarthe D.R.
        • et al.
        Report of a special task force appointed by the steering committee, American Heart Association: Recommendations for human blood pressure determinations by sphygmomanometers.
        Hypertension. 1988; 11: 209A-222A
        • Devereux R.B.
        • Reichek N.
        Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method.
        Circulation. 1977; 55: 613-618
        • Ware Jr, J.E.
        • Sherbourne C.D.
        The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection.
        Med Care. 1992; 30: 473-483
        • McHorney C.A.
        • Ware Jr, J.E.
        • Raczek A.E.
        The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs.
        Med Care. 1993; 31: 247-263
        • Dupuy H.J.
        The Psychological General Well-Being (PGWB) Index.
        in: Wenger N.K. Mattson M.E. Furberg C.D. Elinson J. Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. Le Jacq Publishing, New York1984: 170-183
        • Black H.R.
        • Elliott W.J.
        • Weber M.A.
        • et al.
        One-year study of felodipine or placebo for stage I isolated systolic hypertension.
        Hypertension. 2001; 38: 1118-1123
        • Devereux R.B.
        • Dahlof B.
        • Levy D.
        • Pfeffer M.A.
        Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial).
        Am J Cardiol. 1996; 78: 61-65
        • Haynes R.B.
        Determinants of compliance: The disease and the mechanics of treatment.
        in: Haynes P.B. Taylor D.W. Sackett D.L. Compliance in Health Care. Johns Hopkins University Press, Baltimore1979: 49-62
        • Sharkness C.M.
        • Snow D.A.
        The patient's view of hypertension and compliance.
        Am J Prev Med. 1992; 8: 141-146
        • Smith P.J.
        • Talbert R.L.
        Sexual dysfunction with antihypertensive and antipsychotic agents.
        Clin Pharm. 1986; 5: 373-384
        • Stevenson J.G.
        • Umstead G.S.
        Sexual dysfunction due to antihypertensive agents.
        Drug Intell Clin Pharmacol. 1984; 18: 113-121
        • Trimmer E.
        Sex problems in practice. Iatrogenic sex problems.
        Br Med J (Clin Res Ed). 1981; 283: 953-955
        • Papadopoulos C.
        Cardiovascular drugs and sexuality: A cardiologist's review.
        Arch Intern Med. 1980; 140: 1341-1345
        • Moss H.B.
        • Procci W.R.
        Sexual dysfunction associated with oral antihypertensive medication: A critical survey of the literature.
        Gen Hosp Psychiatry. 1982; 4: 121-129
        • Sackett D.L.
        • Haynes R.B.
        • Gibson E.S.
        • et al.
        Randomised clinical trial of strategies for improving medication compliance in primary hypertension.
        Lancet. 1975; 1: 1205-1207
        • Hedstrand H.
        • Aberg H.
        Treatment of hypertension in middle-aged men. A feasibility study in a community.
        Acta Med Scand. 1976; 199: 281-288
        • Clark L.T.
        Improving compliance and increasing control of hypertension: Needs of special hypertensive populations.
        Am Heart J. 1991; 121: 664-669
        • Eisen S.A.
        • Miller D.K.
        • Woodward R.S.
        • et al.
        The effect of prescribed daily dose frequency on patient medication compliance.
        Arch Intern Med. 1990; 150: 1881-1884
        • Melis M.S.
        • Sainati A.R.
        Effect of calcium and verapamil on renal function of rats during treatment with stevioside.
        J Ethnopharmacol. 1991; 33: 257-262
      37. Evaluation of certain food additives. Fifty-first report of the Joint FAO/WHO Expert Committee on Food Additives.
        World Health Organ Tech Rep Ser. 2000; 891: i-viii
      38. Evaluation of certain food additives. Fifty-first report of the Joint FAO/WHO Expert Committee on Food Additives.
        World Health Organ Tech Rep Ser. 2000; 891: 1-168
        • Huxtable R.J.
        Pharmacology and toxicology of stevioside, rebaudioside A, and stevial.
        in: Kinghorn D. The Genus Stevia. Taylor and Francis, New York2002: 160-177
        • Lee C.N.
        • Wong K.L.
        • Liu J.C.
        • et al.
        Inhibitory effect of stevioside on calcium influx to produce antihypertension.
        Planta Medica. 2001; 67: 796-799
        • Beto J.A.
        • Bansal V.K.
        Quality of life in treatment of hypertension: A metaanalysis of clinical trials.
        Am J Hypertens. 1992; 5: 125-133
        • Hjemdahl P.
        • Wiklund I.K.
        Quality of life on antihypertensive drug therapy: Scientific end-point or marketing exercise?.
        J Hypertens. 1992; 10: 1437-1446
        • Jern S.
        • Zanchetti A.
        The issue of quality of life in antihypertensive therapy.
        J Hum Hypertens. 1993; 7: S46-S49
        • Croog S.H.
        • Levine S.
        • Testa M.A.
        • et al.
        The effects of antihypertensive therapy on the quality of life.
        N Engl J Med. 1986; 341: 1657-1664
        • Testa M.A.
        • Anderson R.B.
        • Nackley J.F.
        • Hollenberg N.K.
        • Quality-of-Life Hypertension Group
        Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril.
        N Engl J Med. 1993; 328: 907-913

      Article info

      Publication history

      Accepted: September 11, 2003

      Identification

      DOI: https://doi.org/10.1016/S0149-2918(03)80334-X

      Copyright

      © 2003 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX